Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa

• Status: Completed
• Trial end date: 2018-09-23
• Target enrollment: 0
• Participant gender: All

Summary

Randomized double blind placebo controlled pilot study/proof of concept-study to see if intradermal injection with Botulinum toxin B is an effective treatment of Hidradenitis suppurativa

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital of North Norway
• Collaborators: Hidrosis Clinic, Stockholm, Sweden; The Royal Norwegian Ministry of Health
• Treatments: Botulinum Toxins; Botulinum Toxins, Type A; rimabotulinumtoxinB

Criteria

Inclusion Criteria:

• Patients with active hidradenitis in the stage I-III according to Hurleys classification. Patients are referred to a dermatology out-patient clinic or patients already in an established treatment program, where there is indication for new or different treatment, or surgical intervention. Patients must have typical affection of the disease of either axillae, groins, and/or perigenital/perianal area

Exclusion Criteria:

• Patients in need of emergency medical or surgical treatment of hidradenitis will be excluded until the disease is in a quiet, controlled phase.

Pregnant or lactating, as well as patients with neurological disease such as myasthenia gravis or motor neuron disease.